ClinicalTrials.gg
Status unknownNCT04139135Updated Jun 6, 2022

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

A Phase 3 interventional study of HLX10 and Placebos in Gastric Cancer, sponsored by Shanghai Henlius Biotech. Status unknown at 15 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-06.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
642
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing serplulimab in Stomach Neoplasms — 8 open to participants now, 11 under way, none of them phase 3. serplulimab · Stomach Neoplasms.

Planned enrollment
Largest of 14
642 · median 59
Started
2019
the only one that year
Phase 3
Only one
of the 14
Registered
1st of 14
by date
Lead sponsor
2 of 14
Shanghai Henlius Biotech

Among the 14 studies testing serplulimab in Stomach Neoplasms, this one has the largest planned enrollment, is the only one that started in 2019, is the only one in phase 3, and was the 1st registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 14 studies testing serplulimab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About serplulimab

serplulimab: first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing serplulimab in Stomach Neoplasms, or all of them as a file.
02

Study summary

This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the efficacy of HLX10 combined with chemotherapy versus placebo combined with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer.

Subjects will be randomized to the following two arms at 1: 1 ratio:

  • Arm A (HLX10 arm): HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase;
  • Arm B (control arm): Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.

Chemotherapy regimen SOX (oxaliplatin + tegafor gimeracil oteracil potassium (S-1)) will be used in the neoadjuvant treatment phase in Arm A and B, and in the adjuvant treatment phase in Arm B.

After randomization, subjects will receive a total of 3 cycles of neoadjuvant treatment with the mentioned treatment regimen.Surgery will be performed within 3-6 weeks after the last cycle of neoadjuvant treatment.All subjects who have completed the surgery will be unblinded after surgery, and adjuvant treatment will be started 3 to 12 weeks after surgery. Subjects randomized to Arm A (HLX10 arm) will continue to receive HLX10 monotherapy for up to 17 cycles (12 months).Subjects in Arm B after surgery (control arm) will continue to use chemotherapy alone (oxaliplatin + S-1) for 5 cycles.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in the clinical study; fully understands and is informed of the study and has signed the Form (ICF); willing to comply with and able to complete all trial procedures.
  2. The gender is not limited. When ICF is signed, the age is ≥ 18 years and ≤ 70 years old.
  3. confirmed untreated gastric cancers, mainly adenocarcinoma.
  4. Within 4 weeks prior to first dose, determined by the Independent Radiology Review Committee (IRRC) as: ≥ T3 and number of lymph node ≥ 1 and no distant metastasis.
  5. Prior to enrollment, the attending physician will evaluate to determine the eligibility for a R0 resection for the purpose of radical treatment.
  6. Have good cardiac function and can be treated with radical resection.
  7. tumor specimen testing results are positive (CPS ≥5). Subjects must provide the tumor tissues at screening or in the investigated surgery (if any), for PD-L1 expression level assessment.
  8. Within 7 days before the first use of the study drug, : 0 \~ 1;
  9. Expected survival 12 weeks;
  10. The functions of the vital organs meet requirements.

Exclusion criteria

Exclusion Criteria:

  1. Existence of other active malignant tumors within 5 years or at the same time.
  2. Plan to perform or have undergone an organ or bone marrow transplant.
  3. Myocardial infarction and poorly controlled arrhythmias occurred within 6 months prior to the first dose.
  4. Existence of grade III - IV cardiac disorders defined by the or echocardiogram shows: (left ventricular ejection fraction) \< 50%.
  5. (HIV) infection.
  6. Patients with active tuberculosis.
  7. Patient with previous or current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia, severely impaired lung function, etc.
  8. Patients who have previously received other antibody/drug treatments for immune checkpoints, such as , PD-L1, and CTLA4 treatments.
  9. Have diseases that may increase the risk of participating in the study and using the study medications, or other severe, acute, and chronic diseases and therefore are judged by the investigator to be unsuitable for clinical studies.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
642 participants (estimated)

Study arms

  • Experimental
    HLX10

    HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase

    Drug: HLX10

  • Placebo comparator
    Placebo

    Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.

    Drug: Placebos

Interventions

  • DrugHLX10

    neoadjuvant treatment phase:HLX10(4.5mg/kg/3w IV) +SOX, adjuvant treatment phase:HLX10(4.5mg/kg/3w IV)

    Also known as: Recombinant humanized anti-PD-1 monoclonal antibody injection

  • DrugPlacebos

    neoadjuvant treatment phase:placebos(4.5mg/kg/3w IV) +SOX, adjuvant treatment phase:SOX

06

What researchers measure

Primary outcomes

  1. EFS

    event-free survival (assessed by independent radiological review committee (IRRC) based on RECIST v1.1)

    Time frame: from randomizationuntil firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 3 years

Secondary outcomes

  1. EFS

    Event-free survival (assessed by the investigator per RECIST v1.1 criteria)

    Time frame: from randomizationuntil firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 3 years

  2. DFS

    Disease-free survival (assessed by the investigator per RECIST v1.1 criteria)

    Time frame: from the start of surgery to disease recurrence or death (for any reason),assessed up to 3 years

  3. pCR rate

    Pathological complete response (pCR) rate (assessed by central pathology laboratory and the site)

    Time frame: after surgery,an average of 6 months

  4. 5-year OS rate

    5-year overall survival (OS) rate

    Time frame: OS is the time from randomization to death (of any cause),assessed up to 5 years

07

Study locations

15 of 15 sites recruiting
  • Peking University shenzhen hospital
    Shenzhen, Guangdong, China
    Recruiting
  • Affiliated Hospital of Hebei University
    Baoding, China
    Recruiting
    • Aimin Zang, MD · Contact
  • Beijing Cancer Hospital
    Beijing, China
    Recruiting
  • China PLA General Hospital
    Beijing, China
    Recruiting
    • Lin Chen, MD · Contact
  • Peking University International Hospital
    Beijing, China
    Recruiting
    • Jun Liang, MD · Contact
  • Peking University Third Hospital
    Beijing, China
    Recruiting
    • Baoshan Cao, MD · Contact
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, China
    Recruiting
    • Congqiao Jiang, MD · Contact
  • Cangzhou People's Hospital
    Cangzhou, China
    Recruiting
    • Yuankai Bo, MD · Contact
  • Anhui Provincial Hospital
    Hefei, China
    Recruiting
    • Zhiqiang Zhu, MD · Contact
    • Gang Wang, MD · Contact
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, China
    Recruiting
    • Guoping Sun, MD · Contact
  • Linyi Cancer Hospital
    Linyi, China
    Recruiting
    • Qingxu Sun, MD · Contact
  • The Fourth Hospital of Hebei Medical University
    Shijia Zhuang, China
    Recruiting
    • Yong Li, MD · Contact
  • Shanxi Provincial People's Hospital
    Taiyuan, China
    Recruiting
    • Xiaogang Bi, MD · Contact
  • Tianjin Medical University Institute & Hospital
    Tianjin, China
    Recruiting
    • Yi Ba, MD · Contact
  • Xingtai People's Hospital
    Xingtai, China
    Recruiting
    • Zhibin Huo, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Oct 2023, 46 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's planned 46 months is close to that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2019
First posted
Oct 25, 2019
StartActual
Dec 12, 2019
Primary completionEst.
Oct 2023
CompletionEst.
Oct 2024
Last update
Jun 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04139135
Responsible party
Sponsor
First posted
Oct 25, 2019
Start date
Dec 12, 2019
Primary completion
Oct 2023 (estimated)
Completion
Oct 2024 (estimated)
Last update
Jun 6, 2022

Study contacts

Jiafu JI
Contact
jijiafu@hsc.pku.edu.cn
010-88140650
Lin Shen
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serplulimab

Start the discussion